Test-Retest Repeatability of Patlak Slopes versus Standardized Uptake Values for Hypermetabolic Lesions and Normal Organs in an Oncologic PET/CT Population.

IF 3 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Molecular Imaging and Biology Pub Date : 2024-04-01 Epub Date: 2024-03-11 DOI:10.1007/s11307-024-01909-x

Semra Ince, Richard Laforest, Saeed Ashrafinia, Anne M Smith, Richard L Wahl, Tyler J Fraum

{"title":"Test-Retest Repeatability of Patlak Slopes versus Standardized Uptake Values for Hypermetabolic Lesions and Normal Organs in an Oncologic PET/CT Population.","authors":"Semra Ince, Richard Laforest, Saeed Ashrafinia, Anne M Smith, Richard L Wahl, Tyler J Fraum","doi":"10.1007/s11307-024-01909-x","DOIUrl":null,"url":null,"abstract":"Purpose: We aimed to determine the test-retest repeatability of quantitative metrics based on the Patlak slope (PS) versus the standardized uptake value (SUV) among lesions and normal organs on oncologic [18F]FDG-PET/CT.Procedures: This prospective, single-center study enrolled adults undergoing standard-of-care oncologic [18F]FDG-PET/CTs. Early (35-50 min post-injection) and late (75-90 min post-injection) SUV and PS images were reconstructed from dynamic whole-body PET data. Repeat imaging occurred within 7 days. Relevant quantitative metrics were extracted from lesions and normal organs. Repeatability was assessed via mean test-retest percent changes [T-RT %Δ], within-subject coefficients of variation (wCVs), and intra-class correlation coefficients (ICCs).Results: Nine subjects (mean age, 61.7 ± 6.2 years; 6 females) completed the test-retest protocol. Four subjects collectively had 17 [18F]FDG-avid lesions. Lesion wCVs were higher (i.e., worse repeatability) for PS-early-max (16.2%) and PS-early-peak (15.6%) than for SUV-early-max (8.9%) and SUV-early-peak (8.1%), with similar early metric ICCs (0.95-0.98). Lesion wCVs were similar for PS-late-max (8.5%) and PS-late-peak (6.4%) relative to SUV-late-max (9.7%) and SUV-late-peak (7.2%), with similar late metric ICCs (0.93-0.98). There was a significant bias toward higher retest SUV and PS values in the lesion analysis (T-RT %Δ [95% CI]: SUV-late-max, 10.0% [2.6%, 17.0%]; PS-late-max, 20.4% [14.3%, 26.4%]) but not in the normal organ analysis.Conclusions: Among [18F]FDG-avid lesions, the repeatability of PS-based metrics is similar to equivalent SUV-based metrics at late post-injection time points, indicating that PS-based metrics may be suitable for tracking response to oncologic therapies. However, further validation is required in light of our study's limitations, including small sample size and bias toward higher retest values for some metrics.","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-024-01909-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We aimed to determine the test-retest repeatability of quantitative metrics based on the Patlak slope (PS) versus the standardized uptake value (SUV) among lesions and normal organs on oncologic [¹⁸F]FDG-PET/CT.

Procedures: This prospective, single-center study enrolled adults undergoing standard-of-care oncologic [¹⁸F]FDG-PET/CTs. Early (35-50 min post-injection) and late (75-90 min post-injection) SUV and PS images were reconstructed from dynamic whole-body PET data. Repeat imaging occurred within 7 days. Relevant quantitative metrics were extracted from lesions and normal organs. Repeatability was assessed via mean test-retest percent changes [T-RT %Δ], within-subject coefficients of variation (wCVs), and intra-class correlation coefficients (ICCs).

Results: Nine subjects (mean age, 61.7 ± 6.2 years; 6 females) completed the test-retest protocol. Four subjects collectively had 17 [¹⁸F]FDG-avid lesions. Lesion wCVs were higher (i.e., worse repeatability) for PS-early-max (16.2%) and PS-early-peak (15.6%) than for SUV-early-max (8.9%) and SUV-early-peak (8.1%), with similar early metric ICCs (0.95-0.98). Lesion wCVs were similar for PS-late-max (8.5%) and PS-late-peak (6.4%) relative to SUV-late-max (9.7%) and SUV-late-peak (7.2%), with similar late metric ICCs (0.93-0.98). There was a significant bias toward higher retest SUV and PS values in the lesion analysis (T-RT %Δ [95% CI]: SUV-late-max, 10.0% [2.6%, 17.0%]; PS-late-max, 20.4% [14.3%, 26.4%]) but not in the normal organ analysis.

Conclusions: Among [¹⁸F]FDG-avid lesions, the repeatability of PS-based metrics is similar to equivalent SUV-based metrics at late post-injection time points, indicating that PS-based metrics may be suitable for tracking response to oncologic therapies. However, further validation is required in light of our study's limitations, including small sample size and bias toward higher retest values for some metrics.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肿瘤 PET/CT 群体中高代谢病变和正常器官的 Patlak 斜率与标准化摄取值的测试-重测重复性。

目的：我们旨在确定基于帕特拉克斜率（PS）的定量指标与标准化摄取值（SUV）在肿瘤[18F]FDG-PET/CT病变和正常器官之间的测试重复性：这项前瞻性单中心研究招募了接受标准护理肿瘤[18F]FDG-PET/CT检查的成人。根据动态全身 PET 数据重建早期（注射后 35-50 分钟）和晚期（注射后 75-90 分钟）SUV 和 PS 图像。7 天内进行重复成像。从病变和正常器官中提取相关的定量指标。重复性通过平均测试-重复测试百分比变化[T-RT %Δ]、受试者内变异系数（wCV）和类内相关系数（ICC）进行评估：九名受试者（平均年龄为 61.7 ± 6.2 岁；六名女性）完成了测试-重测方案。四名受试者共有 17 个[18F]FDG-avid 病变。PS-早期-最大值（16.2%）和PS-早期-峰值（15.6%）的病灶wCV值高于SUV-早期-最大值（8.9%）和SUV-早期-峰值（8.1%）（即重复性更差），早期指标ICC值（0.95-0.98）相似。相对于SUV-late-max（9.7%）和SUV-late-peak（7.2%），PS-late-max（8.5%）和PS-late-peak（6.4%）的病变wCV相似，晚期指标ICC相似（0.93-0.98）。在病变分析中，重测 SUV 和 PS 值明显偏高（T-RT%Δ [95% CI]：SUV-后期最高值，10.0% [2.6%，17.0%]；PS-后期最高值，20.4% [14.3%，26.4%]），但在正常器官分析中却没有：结论：在[18F]FDG显像病灶中，基于PS的指标在注射后晚期时间点的可重复性与等效的基于SUV的指标相似，这表明基于PS的指标可能适用于追踪对肿瘤疗法的反应。不过，鉴于我们研究的局限性，包括样本量较小和某些指标的重测值偏高，因此还需要进一步验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.